

Gaudium IVF introduces AI-led infertility treatment

02 April 2026 | News

The company plans to open 19 new centres across India in the near future



Gaudium IVF, an innovation leader and a pioneering force in India's fertility healthcare sector, has introduced artificial intelligence (AI)-led infertility treatment, marking yet another industry first—just one month after becoming India's first publicly listed IVF chain.

The development involves the integration of advanced AI-driven embryology systems, including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), into routine clinical practice.

This integration has been undertaken in collaboration with IVF 2.0, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr Jacques Cohen and Dr Alejandro Chave. This partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.

Commenting on the development, Dr Manika Khanna, Chairperson and Managing Director, Gaudium IVF, said, "Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey. Our collaboration with IVF 2.0 ensures that global innovations are now accessible to patients within India."

Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates. By improving precision and consistency, the adoption of AI has the potential to reduce the need for repeat cycles, thereby lowering the emotional, physical, and financial burden on patients while inspiring confidence among clinicians and stakeholders.